Trials have initiated treatment at a lower dose, with scheduled increases every four weeks to allow for monitoring of tolerability and side effects
2 The development of and approval of new antihyperglycemic medications has favored the use of different pharmacological families with remarkable properties for the management of additional comorbidities such as renal disease, cardiovascular disease, and non-alcoholic fatty liver disease, that are highly prevalent in this subset
The precise escalation regimen for any future approved formulation may differ substantially from trial protocols
By acting on GLP-1, GIP, and glucagon receptors, Retatrutide is considered a GGG tri-agonist
Symptoms include severe, persistent abdominal pain radiating to the back, often accompanied by nausea and vomiting that differs qualitatively from the typical GI side effects